Rabies shot reveals immune secrets in CAR-T cancer survivors
NCT ID NCT04410900
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed phase 1 trial gave the rabies vaccine to 49 people who had previously received CAR-T therapy for B-cell cancers, along with healthy volunteers for comparison. The goal was to see if their immune systems could mount a normal response to a vaccine. By measuring rabies antibodies in the blood, researchers hope to learn how well the immune system recovers after CAR-T treatment, which could guide future infection prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rabies vaccine (Imovax Rabies)
- What this could lead to
- If successful, this study could help doctors understand how well the immune system works after CAR-T therapy, leading to better infection prevention strategies for these patients.
- What could go wrong
- This is a small, early-phase study that only measures immune response to a vaccine, not a treatment itself. Results may not apply to all patients or predict real-world infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.